Evaluation of Renin-Angiotensin-Aldosterone System and Endothelial-1 Cells Levels in Chronic Renal Failure
DOI:
https://doi.org/10.61841/ynnjd265Keywords:
End-stage Renal Disease (ESRD), Hormonal Abnormalities, ET-1Abstract
End-stage renal disease (ESRD) communicates high mortality risk by complex mechanisms not fully explained but probably linked to hormonal abnormalities, including aldosterone. The point of this examination is to assess the capacity of the renin-aldosterone-angiotensin II framework with endothelial-1 cells. The examination was structured on 176 Iraqi subjects aged 30-70 years with interminable renal failure. The subjects engaged with this examination were 44 hemodialysis patients (30 males and 14 females). ET-1 cell levels increased in chronic renal failure patients, and there was more of a rise in dialysis. Renin angiotensin aldosterone system progress deteriorates begin in stage 4, but more deterioration in dialysis stage
Downloads
References
[1] Matsukawa T, Gotoh E and Minamisawa K (1991) Effects of intravenous infusions of angiotensin II on
muscle sympathetic nerve activity in humans. Am. J. Physiol. 30, R690–R696.
[2] Funder J W (2009) Reconsidering the roles of the mineralocorticoid receptor. Hypertension 53, 286-290.
[3] Drechsler C, Ritz E, Tomaschitz A, Pilz S, Schönfeld S, Blouin K, Bidlingmaier M, Hammer F, Krane V,
März W, Allolio B, Fassnacht M and Wanner C (2013) Aldosterone and cortisol affect the risk of sudden
cardiac death in hemodialysis patients. Eur. Heart J. 34, 578-587.
[4] Letizia C, Iannaccone A, Cerci S, Santi G, Cilli M, Coassin S, Pannarale MR, Scavo D (1997) Circulating
endothelin-1 in non-insulin-dependent diabetic patients with retinopathy. Horm Metab Res.; 29:247–251.
[5] Koyama H, Tabata T, Nishizawa Y, Inoue T, Morii H, Yamaji T. (1989 ) Plasma endothelin levels in
patients with uremia. Lancet., 1: 991–992
[6] Rossi GP, Colonna S, Pavan E, Albertin G, Della Rocca F, Gerosa G, Casarotto D, Sartore S, Pauletto P,
Pessina AC (1999) Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo. Circulation
99: 1147–1155,
[7] Cardillo C, Kilcoyne CM, Waclawiw M, Cannon RO 3rd, Panza JA (1999) Role of endothelin in the
increased vascular tone of patients with essential hypertension. Hypertension 33: 753–758.
[8] Zoccali C, Leonardis D, Parlongo S, Mallamaci F, Postorino M (1995) Urinary and plasma endothelin-1 in
essential hypertension and in hypertension secondary to renoparenchymal disease. Nephrol Dial Transplant
10: 1320–1323,
[9] Kohno M, Murakawa K, Yasunari K, Yokokawa K, Horio T, Kurihara N, Takeda T (1989) Prolonged
Blood pressure elevation after endothelin administration in bilaterally nephrectomized rats. Metab Clin Exp
38: 712–713,
[10] Benz K, (2011) Amann K, Endothelin in diabetic renal disease, Contrib Nephrol;172:139–48.
[11] Peppa-Patrikiou M, Dracopoulou M, Dacou-Voutetakis C (1998) Urinary endothelin in adolescents and young adults with insulin-dependent diabetes mellitus: relation to urinary albumin, blood pressure, and other factors. Metabolism; 47:1408–12
[12] Cottone, S., Mule, G., Guarneri, M., Palermo, A., Lorito, M.C., Riccobene, R., Arsena, R., Vaccaro, F., Vadala, A., Nardi, E., Cusimano, P. & Cerasola, G. (2009). Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients. Nephrol Dial Transplant, 24, 497-503
[13] Deray, G., Carayon, A., Maistre, G., Benhmida, M., Masson, F., Barthelemy, C., Petitclerc, T. & Jacobs, C.
(1992). Endothelin in chronic renal failure. Nephrol Dial Transplant, 7, 300-5.
[14] Goddard, J., Johnston, N.R., Cumming, A.D. & Webb, D.J. (2007). Fractional urinary excretion of
Endothelin-1 is reduced by acute ETB receptor blockade. Am JPhysiol Renal Physiol, 293, F1433-8.
[15] Vlassopoulos, D., Deray, G., Carayon, A., Maistre, G. & Jacobs, C. (1995). Blood and peritoneal levels of
endothelin in continuous ambulatory peritoneal dialysis patients. Nephron, 69, 273-6
[16] Abdullah Hasan Jabbar et al, 2020, ''Green Synthesis and Characterization of Silver Nanoparticle (AgNPs)
using Pandanus Atrocarpus Extract,'' International Journal of Advanced Science and Technology, 29 (3),
4913-4922.
[17] Goddard, J., Johnston, N.R., Cumming, A.D. & Webb, D.J. (2007). Fractional urinary excretion of
Endothelin-1 is reduced by acute ETB receptor blockade. Am JPhysiol Renal Physiol, 293, F1433-8.
[18] Warrens, A.N., Cassidy, M.J., Takahashi, K., Ghatei, M.A. & Bloom, S.R. (1990). Endothelin in renal
failure. Nephrol Dial Transplant, 5, 418-420.
[19] Cardillo C, Campia U, Bryant MB, Panza JA (2002) Increased activity of endogenous endothelin in
patients with type II diabetes mellitus. Circulation. 106: 1783–1787.
[20] Bauer C, Melamed ML, Hostetter H (2008) Staging of chronic kidney disease: time for a course correction. J
Am Soc Nephrol; 19: 844-6.
[21] ADMA, Yilmaz MI, Sonmez A, Saglam M, et al. (2008) levels correlate with proteinuria, secondary
amyloidosis, and endothelial dysfunction. J Am Soc Nephrol.; 19: 388–395.
[22] Frank, R. D. et al. (2005) The synthetic pentasaccharide fondaparinux reduces coagulation, inflammation,
and neutrophil accumulation in kidney ischemia-reperfusion injury. J. Thromb. Haemost. 3, 531–540
[23] Karet FE, Davenport AP (1996) Localization of endothelin peptides in human kidney. Kidney Int., 49:382–
387.
[24] Sakamoto A, Yanagisawa M, Takuwa Y, Masaki T (2001) Cloning and functional expression of human cDNA for the ETB endothelin receptor. Biochemical and Biophysical Research Communications; 178:656–63.
[25] Ali Jabbar Abdullah (2018), "Effect of climate change on occurrence of the vectors borne and infectious disease," Journal of Global Pharma Technology, 10 (08): 159-164.
[26] Mezzogiorno, A., Mezzogiorno, V., Esposito, V. (2002). History of the nephron. Am J Nephrol 22, 213.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
